Mont-Saint-Guibert, Belgium – October 18, 2022, 10:30 PM CET / 4:30 PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology firm dedicated to developing innovative treatments for Obstructive Sleep Apnea (OSA), has announced that it will release its financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after the market closes. Following the release, company management will hold a conference call at 10:30 PM CET / 4:30 PM ET to discuss the results.
Investors wishing to participate in the conference call can register for a unique personal PIN using the following link: Registration Link. A live and archived webcast of the event will be accessible on Nyxoah’s investor relations website at Nyxoah Investor Relations.

About Nyxoah

Nyxoah is committed to advancing medical technology for the treatment of Obstructive Sleep Apnea (OSA). The company’s flagship solution is the Genio® system, a leadless and battery-free hypoglossal neurostimulation therapy designed to address OSA, a prevalent sleep disorder linked to increased mortality and cardiovascular issues. Nyxoah envisions that patients suffering from OSA can achieve restful sleep and fully engage in life.

The Genio® system received its European CE Mark in 2019 after the successful completion of the BLAST OSA study. Nyxoah has successfully conducted two initial public offerings: one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021. Following the favorable results of the BETTER SLEEP study, Nyxoah expanded its CE mark approval to include Complete Concentric Collapse (CCC) patients, a population currently excluded from competing therapies. Additionally, the company is conducting the DREAM IDE pivotal study to seek FDA approval for commercialization in the U.S.